macrophage along superficial dermis. Patient give
therapy emolient baby cream two times daily, and
education about patient’s condition, posibility of
opthalmologic or neurologic condition, consult if
there’s any complain and not manipulate the lesion.
The absence of severe systemic complications
was noted in 43 of 96 (44.8%) patients with
generalized IP and 39 of 43 (90.7%) IP patients with
minor cutaneous symptoms (Hadj-Rabia et al., 2011).
In this case, there was a skin anomali but with no
other organ involvement. This patient is female, with
history of her mother miscarriage in second child.
Cutaneous manifestations: Stage 1, inflammatory
or vesicular stage: development of papules, vesicles
and pustules on an erythematous base, distributed
linearly along the lines of Blaschko. Stage 2,
verrucous stage, is characterized by plaques and
warty papules linearly arranged over an erythematous
base, also following the lines of Blaschko. Stage 3 or
hyperpigmented stage : development of linear or
whorled lesions, with a brownish pigmentation,
which may be accompanied by atrophy, occurs in 90-
98% . Stage 4, known as atrophic or hypopigmented,
is characterized by areas of hypopigmentation,
atrophy and absence of hair.develop during
adolescence, persist into adulthood.
On this case, histopathological examination
showed on epidermis there were hiperkeratosis basal
cell, no spongiosis. On dermis there were melanin
within macrophage along superficial dermis. There
were some lymphocyte. No eosinophil. This is more
like the third stage of IP.
Although the skin lesions of IP appear impressive,
little treatment is needed as they will gradually clear
on their own. Parents should be appropriately
counseled about the expected course of the disease. A
bland emollient can be applied to inflammatory
lesions to prevent ulceration. If ulceration occurs,
antibiotic ointment and non-adherent sterile dressings
should be used to cover the affected areas. Subungal
tumors may spontaneously resolve, but can be treated
with surgical excision or curretage to ameliorate the
associated pain (Brucker, 2004; Julie et al., 2013).
REFERENCES
Berlin, A.L., Paller, A.S., Chan, L.S., 2002. Incontinentia
pigmenti: A review and update on the molecular basis of
pathophysiology. Journal of the American Academy of
Dermatology. doi:10.1067/mjd.2002.125949
Bruckner, A.L., 2004. Incontinentia pigmenti: a window to
the role of NF-kappaB function. Seminars in cutaneous
medicine and surgery 23, 116–24.
doi:10.1016/j.sder.2004.01.005
Hadj-Rabia, S., Froidevaux, D., Bodak, N., Hamel-Teillac,
D., Smahi, A., Touil, Y., Fraitag, S., De Prost, Y.,
Bodemer, C., 2003. Clinical study of 40 cases of
incontinentia pigmenti. Archives of Dermatology 139,
1163–1170. doi:10.1001/archderm.139.9.1163
Hadj-Rabia, S., Rimella, A., Smahi, A., Fraitag, S., Hamel-
Teillac, D., Bonnefont, J.P., De Prost, Y., Bodemer, C.,
2011. Clinical and histologic features of incontinentia
pigmenti in adults with nuclear factor-κB essential
modulator gene mutations. Journal of the American
Academy of Dermatology 64, 508–515.
doi:10.1016/j.jaad.2010.01.045
Hegde, S., Bhat, S., Soumya, S., Pai, D., 2006.
Incontinentia pigmenti. Journal of Indian Society of
Pedodontics and Preventive Dentistry 24, S24–S26.
Hilde, L., Barbara, B., Sofie, D.S. 2012. Diffuse Linear
Hypermelanosis. In: Goldsmith LA, Katz SI, Gilchrest
BA, Paller AS, Leffell DJ, W.K. (Ed. 8), Fitzpatrick’s
Dermatology in General Medicine. McGraw Hill, New
York Chicago, pp. 814
Minić, S., Trpinac, D., Obradović, M., 2014. Incontinentia
pigmenti diagnostic criteria update. Clinical Genetics
85, 536–542. doi:10.1111/cge.12223
Nelson, D.L., 2006. NEMO, NFκB signaling and
incontinentia pigmenti. Current Opinion in Genetics
and Development. doi:10.1016/j.gde.2006.04.013
Welch, J.L., Jimenez, H.L., Allen, S.E., 2013. Pediatric
rash: Dermatologic manifestations of incontinentia
pigmenti. Journal of Emergency Medicine 45.
doi:10.1016/j.jemermed.2013.01.040
Zhang, Y., Pyla, V., Cong, X., 2013. Incontinentia pigmenti
(Bloch-Siemens syndrome). European Journal of
Pediatrics 172, 1137–1138. doi:10.1007/s00431-013-
1982-y
Zou, C.C., Zhao, Z.Y., 2007. Clinical and molecular
analysis of NF-kappaB essential modulator in Chinese
incontinentia pigmenti patients. Int J Dermatol 46,
1017–1022. doi:IJD3365 [pii]\r10.1111/j.1365-
4632.2007.03365.x